Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27125299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Junaid Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy. Hauptthemen laut MEDLINE: Zinc Oxide, Gold, Neoplasms, Metal Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, “RADIATIONS”, National Center 5 “National Biodiversity Future Center”.
Abstract (Originalsprache)
Radiolabelled nanoparticles are increasingly investigated as multifunctional platforms for cancer imaging, biodistribution tracking, dosimetry, and radionuclide-based therapy. This review focuses on three representative inorganic nanoplatforms: zinc oxide (ZnO), iron oxide-based, and gold (Au) nanoparticles. These systems were selected because they combine distinct physicochemical properties with versatile surface engineering and radiolabelling strategies. ZnO nanoparticles offer pH-responsive behaviour and drug-delivery potential; iron oxide-based nanoparticles provide magnetic functionality, Magnetic resonance imaging (MRI) compatibility, and opportunities for magnetic hyperthermia or local nanobrachytherapy; and Au nanoparticles enable stable surface functionalization, radiometal chelation, radiosensitisation, photothermal effects, and alpha or beta-emitter-based local therapy. The review critically discusses synthesis and surface-modification methods, chelator-mediated and chelator-free radiolabelling, coating-assisted and anchoring-mediated strategies, and the influence of these factors on radiochemical stability, biodistribution, tumour uptake, therapeutic response, toxicity, and clearance. A function-based comparison of the reviewed studies highlights that many systems demonstrate efficient radiolabelling and imaging capability, whereas fewer provide direct in vivo therapeutic efficacy, long-term toxicity, or metabolic clearance data. Overall, radiolabelled ZnO, iron oxide-based, and Au nanoparticles show strong potential for cancer theranostics, tumour-to-organ distribution, therapeutic benefit, and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy.
- NBFC-National Biodiversity Future Center, 90133 Palermo, Italy.
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, 90127 Palermo, Italy.
- Advanced Diagnostic Imaging-INNOVA Project, Department of Radiological Sciences, A.R.N.A.S. Civico Di Cristina e Benfratelli Hospitals, P.zza N. Leotta 4, 90127 Palermo, Italy.
ORCID-Profile: Junaid Ali, Albert Comelli, Muhammad Ali, Pierpaolo Alongi, Viviana Benfante
Förderung
- Ministry of Health
- “RADIATIONS”
- National Center 5 “National Biodiversity Future Center”
- Italian Ministry of Health
Zitieren
APA
Ali, J., Comelli, A., Ali, M., Alongi, P., & Benfante, V. (2026). Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27125299
Vancouver
Ali J, Comelli A, Ali M, Alongi P, Benfante V. Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27125299
BibTeX
@article{Ali2026,
author = {Ali, Junaid and Comelli, Albert and Ali, Muhammad and Alongi, Pierpaolo and Benfante, Viviana},
title = {Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27125299}
}
EUVIMED